Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors

被引:6
作者
Tsimafeyeu, Ilya [1 ]
Volkova, Maria [2 ]
Olshanskaia, Anna [2 ]
Raskin, Grigory [3 ]
Aschuba, Saida [4 ]
Khochenkova, Yulia [4 ]
Bondarenko, Anastasia [5 ]
Khochenkov, Dmitry [4 ,6 ]
机构
[1] Kidney Canc Res Bur, Mayakovskogo Pereulok 2 Off 1, Moscow 109147, Russia
[2] NN Blokhin Russian Canc Res Ctr, Dept Urol, Moscow, Russia
[3] AM Granov Russian Sci Ctr Radiol & Surg Technol, St Petersburg, Russia
[4] NN Blokhin Russian Canc Res Ctr, Dept Expt Diagnost & Tumor Therapy, Moscow, Russia
[5] IM Sechenov First Moscow State Med Univ, Moscow, Russia
[6] Togliatti State Univ, Tolyatti, Russia
基金
俄罗斯科学基金会;
关键词
Renal cell carcinoma; Receptor tyrosine kinases; Peripheral blood mononuclear cells; Tumor-infiltrating lymphocytes; Healthy donors; GROWTH; THERAPY;
D O I
10.1159/000505373
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Very little is known about receptor tyrosine kinase (RTK) expression on peripheral blood mononuclear cells (PBMC) in humans including renal cell carcinoma (RCC) patients. Objectives: The primary objective of this study was to evaluate expression levels of major RTKs on PBMC and tumor-infiltrating lymphocytes (TIL) isolated from RCC patients. The secondary aim was to compare levels of RTK expression in RCC patients before surgery and on the 180th day after surgery (lymphocyte lifetime) and to compare them with the expression in healthy donors. In addition, we compared RTK and PD-L1 expression in TIL. Methods: Tumor and blood samples were obtained from 20 patients with primary RCC immediately after surgical resection. Blood samples were collected from 20 healthy donors. Tumors were harvested into RPMI 1640 medium (Gibco) and processed within 4 h. TIL isolation was performed using a modified protocol [Baldan et al. Br J Cancer. 2015;112:1510-18]. Expression of RTKs was evaluated with NovoExpress Software. Twenty tumors from the same patients were stained with PD-L1 IHC assay (clone SP142; Ventana). Results: PBMC and TIL express RTKs in humans. The RTK expression level was significantly lower on peripheral blood cells in patients with RCC (mean 41%, range 27.1-62.6%) as compared with healthy donor PBMC (mean 77.1%, range 72.1-80.1%, all p < 0.05). Furthermore, RTK expression was significantly downregulated on intratumoral cells (mean 40%, range 23.2-52.3%) in comparison with healthy donor PBMC. There was no significant recovery of RTK expression on the 180th day except for VEGFR2. Five of 20 (25%) patients were PD-L1 positive. PD-L1 expression on TIL was strongly associated with downregulated expression of PDGFR alpha (p = 0.017) and PDGFR beta (p = 0.024). Conclusions: PBMC and TIL had similar low RTK expression levels in RCC patients. PBMC of healthy humans had a significantly higher expression of RTK. PD-L1 and PDGFR alpha-beta expression could correlate. Comprehensive basic and clinical studies will be needed to define a biological role of RTKs on different lymphocyte subsets and correlations between clinical outcomes and expression levels.
引用
收藏
页码:252 / 258
页数:7
相关论文
共 9 条
  • [1] Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
    Baldan, V.
    Griffiths, R.
    Hawkins, R. E.
    Gilham, D. E.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1510 - 1518
  • [2] Receptor tyrosine kinases: mechanisms of activation and signaling
    Hubbard, Stevan R.
    Miller, W. Todd
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2007, 19 (02) : 117 - 123
  • [3] Manash K., 2004, INT J MEDICAL SCI, V1, P101, DOI DOI 10.7150/IJMS.1.101
  • [4] Resistance to targeted therapy in renal-cell carcinoma
    Rini, Brian I.
    Atkins, Michael B.
    [J]. LANCET ONCOLOGY, 2009, 10 (10) : 992 - 1000
  • [5] Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell Carcinoma
    Tsimafeyeu, Ilya
    Bratslavsky, Gennady
    [J]. ONCOLOGY, 2015, 88 (06) : 321 - 331
  • [6] OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model
    Tsimafeyeu, Ilya
    Zaveleva, Elina
    Stepanova, Evgenia
    Low, Walter
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1436 - 1443
  • [7] Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
    Tyulyandina, Alexandra
    Harrison, Daniel
    Yin, Wei
    Stepanova, Evgenia
    Kochenkov, Dmitry
    Solomko, Eliso
    Peretolchina, Nina
    Daeyaert, Frits
    Joos, Jean-Baptiste
    Van Aken, Koen
    Byakhov, Mikhail
    Gavrilova, Evgenia
    Tjulandin, Sergei
    Tsimafeyeu, Ilya
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 127 - 133
  • [8] Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
    Wagner, Joel P.
    Wolf-Yadlin, Alejandro
    Sevecka, Mark
    Grenier, Jennifer K.
    Root, David E.
    Lauffenburger, Douglas A.
    MacBeath, Gavin
    [J]. SCIENCE SIGNALING, 2013, 6 (284)
  • [9] RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer
    Zavalishina, Larisa
    Tsimafeyeu, Ilya
    Povilaitite, Patrisia
    Raskin, Grigory
    Andreeva, Yulia
    Petrov, Alexey
    Kharitonova, Ekaterina
    Rumyantsev, Alexey
    Pugach, Inna
    Frank, Georgy
    Tjulandin, Sergei
    [J]. VIRCHOWS ARCHIV, 2018, 473 (06) : 719 - 724